Drug treatments for obesity

From Citizendium
Revision as of 07:56, 5 November 2009 by imported>Bruce Traven McLintock (→‎Orlistat)
Jump to navigation Jump to search

This page was started in the framework of an Eduzendium course and needs to be assessed for quality. If this is done, this {{EZnotice}} can be removed.

This article is developed but not approved.
 Main Article
 Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
https://en.citizendium.org/wiki/index.php?title=Drug_treatments_for_obesity&printable=yes
This editable, developed Main Article is subject to a disclaimer.


Introduction

The current generation of pharmacological interventions for the treatment of obesity is ineffective. Whilst many treatments are promising in the short term; long term maintenance is a key problem that has yet to be overcome. With the ever inceasing prevalence of obesity in the developed, and now developing world, it is an integral concern to epidemiologists, policy makers and scientists looking to treat obesity.

Here we explain the basic mechanisms of action underlying the current pharmacological treatments and also the avenues of development that any future drugs may take. The field of anti-obesity and weight loss pharmacology is one that is in its infancy, and could conceivably be worth billions.

Serotonin & Noradrenaline Related Drugs

Method of Action

Sibutramine is a drug, originally used in the treatment of depression [1], which is now used to help obese and overweight patients lose weight, and along with Orlistat, is the only drug licensed for use in the UK [2]. It acts within the hypothalamus by preventing reuptake of both noradrenaline and serotonin [1][3][4]. This inhibition causes the patient increased feelings of satiety, a decreased appetite, and a corresponding reduced intake of food which results in weight loss [5]. Certain studies have shown that sibutramine may increase thermogenesis and as such, contribute to weight loss, but there have also been other studies in which no such effects were shown, and it seems fair to say that this action seems to only contribute in, at most, a minor way to weight loss. It is also thought that sibutramine may effect levels of the hormones leptin and ghrelin, as well as central neuropeptide Y (NPY), and proopiomelanocortin (POMC) mRNA. Sibutramine treatment differs to orlistat in relation to leptin, as, when using sibutramine, transfer of leptin into the brain is maintained or even increased during weight loss which does not happen when using orlistat [4].

Side-effects

One of the major side-effects of sibutramine therapy is the increase, in a dose-dependent manner, of both blood pressure and heart rate [1][3]. A patient with obesity is likely to already have elevated blood pressure and heart rate, and as a result, if an obese patient is taking sibutramine, it is important to check these levels on a regular basis to make sure they are not too highly elevated [2]. Patients with hypertension and/or cardiovascular disease are strongly advised against taking the drug due to these adverse effects. As well as these side-effects, sibutramine can also on occasion cause the patient to suffer from a dry mouth, constipation and insomnia [6]. Any adolescents taking sibutramine should be regularly checked for a possible increase in suicidal thoughts, as it acts in a similar way to anti-depressants by preventing noradrenaline and serotonin uptake [3].

Endocannabinoids

CB1 receptors

Endocannabinoids are endogenously-made compounds that act on cannabinoid receptors within the central nervous system (CB1) and peripheral tissues (CB2). The CB1 receptors are G-protein coupled receptors, located on the plasma membranes of neurones in specific regions of the brain: the hippocampus; the cerebellum; the hypothalamus; and various dopaminergic 'reward' pathways. [7].

When a cannabinoid compound binds to the CB1 receptor, it has 2 main actions: 1) calcium entry to the cell is inhibited by blocking the calcium channels 2) potassium channels are activated, causing potassium to exit and hyperpolarise the cell

The net effect is that neurotransmitter release is inhibited. This is shown in the diagram below.

Image Caption

Rimonabant

CB1 receptor antagonists, namely the drug rimonabant, have been used in tackling obesity. The link between appetite and the CB1 receptors is unclear, but is likely to be particularly important in those receptors in the hypothalamus. Mice genetically engineered to be deficient in CB-1 receptors have been shown to be resistant to diet induced obesity [20], and clinical trials of rimonabant have demonstrated significant weight loss in obese subjects when combined with a reduction in calorie intake, as well as an improvement the ratio of good (HDL) to bad (LDL) cholesterol.

However, a major issue in using CB1 antagonists is the incidence of psychiatric problems, in particular, depression (unfortunately several suicides occured during trials [30]). As a result, the FDA has not approved the use of rimonabant in the United States. The European Medicines Agency (EMEA) has recommended the marketing authorisation of rimonabant be suspended across the EU, and consequently NICE has withdrawn its guidance for the use of the drug [N4].

Rang + Dale: Ch 15 Cannabinoids p 251-254 Review: The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS. http://eurheartj.oxfordjournals.org/cgi/reprint/ehn255v1.pdf [20] Review: Lifestyle and Pharmacological Approaches to Weight Loss: Efficacy and Safety [29] Rimonabant for the treatment of overweight and obese patients: http://www.nice.org.uk/TA144 [N4]

Peripheral Drugs

Orlistat

‘Peripherally acting anti-obesity drugs’ are another class of medication aimed at causing weight loss in overweight and obese individuals. These work by reducing the calorie intake from food, or altering the metabolism of it in the gastrointestinal system (gut). There is currently only one drug of this kind that is approved for use globally - Orlistat (Xenicol) - and it works by inhibiting the enzyme lipase that breaks down fat in the gut, meaning that the fat cannot be absorbed from food, and instead it is excreted out of the body[8]. Studies have shown that this can reduce the amount of fat absorbed from the gut by 30%, causing a decreased calorie intake and therefore weight loss. The weight loss from taking this medication is found to be between 5-10% on average[9]. As well as weight loss, Orlistat has been shown to improve several other cardiovascular risk-factors. Low-density lipoproteins (LDL) and triglyceride levels were shown to be reduced by 10% more than expected for the weight loss, as well as blood pressure, waist circumference and lipids being reduced[5][10]. Some research also suggests that Orlistat reduces fasting glucose and HbA1c levels in type 2 diabetics by more than predicted for the weight loss, with suggested methods including increased insulin sensitivity and glucagon-like peptide-1 secretion in the small intestine. Orlistat also helps to reduce the risk of type 2 diabetes in obese subjects by 37.3%[5].

However, this drug does not come without some side-effects. Oily-spotting, flatulence, abdominal cramps, faecal urgency/incontinence and liquid stools are the common adverse effects of Orlistat, due to an increase of fat in the gut and stools[8]. These side-effects are reported to only be experienced during the early stages, “but they subside as patients learn to use the drug”[3]. Orlistat also prevents some absorption of fat-soluble vitamins (A,E,D,K), and so patients are recommended to take supplements[8]. The drug does not have any systemic side-effects as it is contained in the gut, however it does affect the absorption of acyclovir, and they shouldn’t be used at the same time[3].

In 2001 the NHS National Institute for Health and Clinical Excellence (NICE) issued a press release on guidance for Orlistat use, and it states that it is cost effective to the NHS[11]. Studies have also shown that Orlistat is a cost-effective drug in obese adults[5].

Amylin

As well as pharmaceutical drugs that work in the periphery to cause weight loss, there are also intrinsic chemicals produced in the body (hormones) that when released cause a feeling of satisfaction and being ‘full up’. These are called satiety signals. One example is Amylin, which is a hormone secreted along with insulin from the pancreas in response to a meal, causing you to feel full, therefore regulating your meal size. An amylin analogue, Pramlintide, is currently being looked into as a potential anti-obesity therapy, with it already being used in diabetics. [10].

Glucagon-like peptide-1

Another example is glucagon-like peptide-1, which is released from the gut during eating, and relays satiety information to the brain via the vagus nerve. This is not yet approved, however, for obesity treatment. [10].

Others

Another hormone secreted in the gut, peptide YY, could also be a potential for use, along with pancreatic polypeptide (PP) – both of which decrease appetite. Small-scale trials in a peptide called Oxyntomodulin have also been promising, with larger trials waiting to be preformed. [10].

Other Drug Therapies

Off Label Uses of Prescribed Medication

There are certain drugs, that are not primarily indicated for use as weight loss therapies; however they may be effective in this role. Below is a list of drugs and the evidence to support or disprove their usefulness as anti-obesity agents.

Anti-Diabetic Medication

Metformin & Acarbose

In patients with type II diabetes, there is evidence to support the use of metformin and acarbose as weight loss agents [12]. The role of metformin in stabilising blood glucose levels has been shown to aid weight loss and also - perhaps by another mechanism - to reduce appetite [13]. Acarbose is believed to simply slow nutrient digestion and interact with Glucagon-like Peptide-1 to aid a slight weight loss [12].

In contrast to this, patients without type II diabetes will not benefit to the same extent although trials have shown minor improvements [9]. In The Diabetes Prevention Program, the weight loss achieved in a group of non-diabetic patients taking metformin was approximately half of that of a 'lifestyle modification' group. And the mean weight loss was only slightly higher than in the placebo group [14]. Acarbose is of even less use in this context, neither helping with weight loss or with maintaining a healthy weight.

Liraglutide

Liraglutide is a long-acting analogue of glucagon-like peptide-1. Effects are a result of mimicking endogenous GLP-1 (see above), with the addition of a reduction in food consumption.

It has recently been shown to be effective in non-diabetic groups [15], resulting in significant weight loss compared to a placebo and orlistat. Liraglutide also reduced fasting lipids and mean systolic blood pressure. With regard to long-term weight maintanence, further studies are still required.

Diuretics

Diuretics, cause an increase in fluid loss (e.g. by means of hypo-absorption in the nephron), and as such have no role in weight loss by reducing body fat stores. They are abused, however as means of a 'quick-fix' pseudo-weight loss, giving the impression of a reduction in body weight whilst in reality, they are simply causing dehyrdration. They have been used for some time in the sporting world, particularly boxing, for boxers to 'make the weight' or simply to reduce likelihood of other drugs being found by urine testing [16]. The are also used by women suffering from pre-menstrual water retention [17].

Thyroid Hormones

One potential method of tackling obesity is the use of thyroid hormone mimetics. Thyroid hormones (T3, T4) act on the thyroid hormone receptors (THR) to elevate the body’s metabolic rate, increasing oxygen consumption leading to an increased use of fat for energy production. However the hormones also have stimulatory effects on the heart rate, causing tachycardia and dangerous arrhythmias, as well as raising the metabolism of muscle protein and promoting bone turnover. [18].

Thyroid hormone mimetics – compounds with similar effects on the fat metabolism without causing any of the unwanted cardiac symptoms – have been developed and tested on animals. One of these named GC-1, an agonist for the thyroid hormone receptor beta 1 (THRB1) has been shown to have minimal effects on the cardiac muscle, whilst stimulating fat metabolism in rats. GC-1 has also been shown to reduce body weight in primates, though this may not specifically be fat loss.

GC-1 and KB2155 (another THRB1 agonist) have been tested in human trials, with no report of weight loss, though this could be due to insufficient doses or the minimal trial period. It remains to be seen what benefit these drugs could offer in humans, both on obesity and on other metabolic conditions. [19]

Caffeine & Ephedrine

Basic mechanism of Action

Caffeine is a stimulant belonging to the xanthine class of drugs. It is an attractive pharmacological agent for consideration in the context of helping people to lose weight, not only because of its wide global availability, social acceptability and price.

Caffeine has been shown to be effective in increasing thermogenesis in humans and reducing appetite, however as a long-term weight loss agent it shows decreased efficacy [20]. This is believed to be because of the tolerance (upregulation of adenosine receptors) that develops to caffeine usage.

Ephedrine is a sympathomimetic amine, which acts as a stimulant and appetite suppressant. It has been shown to have mild efficacy as a weight loss drug and when combined synergistically with caffeine, it have been shown to be very effective for long-term weight loss [21]. However, there are problems associated with the fact both drugs act to increase the outputs of the sympathetic nervous system. These include a rise in blood pressure, palpitations, insomnia and tremor amongst others.

Amphetamines & Cocaine

Cocaine- and Amphetamine- Regulated Transcript (CART) is a peptide produced in the hypothalamus. It plays a role in satiety, in association with leptin and neuropeptin Y (NPY); the former enhances satiety whereas the latter stimulates hunger.

CART production has been shown to decrease in obese animals with dysfunctional leptin signalling, for example in the ob/ob mouse (which cannot produce leptin) and the fa/fa rat (which is resistant to leptin). The same animal models have increased NPY in the hypothalamus, indicating that leptin plays a role in inhibiting the NPY-mediated hunger signalling; this role seems to be partially facilitated by CART, as CART administration to the brain has been shown to inhibit feeding in rats.

In summary, CART appears to stimulate satiety, and is produced in response to leptin. It also inhibits feelings of hunger, perhaps by an interaction with NPY (see the diagram below). Pharmaceutically exploiting its actions could be a potential method of tackling obesity ref>Article: Paper: Hypothalamic CART is a new anorectic peptide regulated by leptin [Kristensen et Al.]</ref>.

The interaction of Leptin, CART and NPY

Conclusion

Obesity levels are increasing at a dramatic rate, and this brings with it a plethora of other associated health conditions. This presents a huge burden to the NHS, both today and in years to come. There are few drugs currently available aimed specifically to help reduce body weight and of these, a large number have prohibitive side-effects. There are a small group of drugs which have the additional benefit of causing weight loss along with their main action (e.g. metformin), but these have been shown to be ineffective purely as anti-obesity medications. Many possibilities are being looked into as a successful method of weight loss treatment, with particular focus on endogenous hormones, and the role they play in diet control, and weight maintenance in humans. A more holistic approach may be the solution, taking into account the role of societal and the psychological issues surrounding excessive weight gain, rather than purely approaching the topic from a pharmacological perspective.

References

  1. ↑ 1.0 1.1 1.2 Woo T (2009) Pharmacotherapy and Surgery Treatment for the Severely Obese Adolescent. Journal of Paediatric Health Care 23:4 pp.206-212
  2. ↑ 2.0 2.1 Rang H, Dale M, Ritter J, Moore P (2007) Pharmacology. Churchill Livingstone, Elsevier. 417-418
  3. ↑ 3.0 3.1 3.2 3.3 3.4 Bray G (2008) Lifestyle and Pharmacological Approaches to Weight Loss: Efficacy and Safety. J Clin Endocrinol metab. 93: S81–S88
  4. ↑ 4.0 4.1 Tziomalos K et al. (2009) The use of sibutramine in the management of obesity and related disorders: An update. Vascular Health and Risk Management 5:1 pp. 441-452.
  5. ↑ 5.0 5.1 5.2 5.3 Coutinho W (2009) The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. Arquivos Brasileiros De Endocrinologia E Metabologia. 53:262-270
  6. ↑ Boon NA, Colledge NR, Walker BR, Hunter JAA (2006) Davidson's Principles & Practice of Medicine 111-117
  7. ↑ Rang H, Dale M, Ritter J, Moore P (2007) Pharmacology. Churchill Livingstone, Elsevier. 441-444
  8. ↑ 8.0 8.1 8.2 Elangbam C.S (2009) Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns. vet pathol. 26:10-24
  9. ↑ 9.0 9.1 Desilets AR, Dhakal-Karki S, Dunican KC. (2008). Role of metformin for weight management in patients without type 2 diabetes. Ann Pharmacotherapy. 42(6):817-26.
  10. ↑ 10.0 10.1 10.2 10.3 Zanella M, Filho F (2009) Emerging drugs for obesity therapy. Arq Bras Endocrinol Metab. 53(2):271-280
  11. ↑ NHS National Institute for Health and Clinical Excellence: Press release (2001), Viewed 7 October 2009,
  12. ↑ 12.0 12.1 Siraj ES. (2003). Is there a role for metformin or acarbose as a weight-loss agent in the absence of diabetes? Cleve Clin J Med. 70(8):702-4.
  13. ↑ Hauptman J, Lucas C, Boldrin M, Collins H (2000) Orlistat in the Long-term Treatment of Obesity in Primary Care Settings. Arch Fam Med 9:160–167
  14. ↑ Knowler WC et al. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.N Engl J Med. 346(6):393-403.
  15. ↑ Astrup A et al. (2009). Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. The Lancet.
  16. ↑ Bulik CM. (1992). Abuse of drugs associated with eating disorders. J Subst Abuse. 4(1):69-90.
  17. ↑ Wagner JC. (1991). Enhancement of athletic performance with drugs. An overview. Sports Med. 12(4):250-65.
  18. ↑ Rang H, Dale M, Ritter J, Moore P (2007) Pharmacology. Churchill Livingstone, Elsevier. 441-444
  19. ↑ Reference: Review: Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes [Baxter J. D.] available -http://www.nature.com/nrd/journal/v8/n4/full/nrd2830.html
  20. ↑ Greenway FL. (2001). The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent. Obes Rev. 2(3):199-211.
  21. ↑ Diepvens K, Westerterp KR, Westerterp-Plantenga MS. (2007). Obesity and thermogenesis related to the consumption of caffeine, ephedrine, capsaicin, and green tea. Am J Physiol. 292(1):R77-85.
Retrieved from "https://citizendium.org/wiki/index.php?title=Drug_treatments_for_obesity&oldid=676462"